ERK inhibitor

DRUG CLASS:

ERK inhibitor

News alerts, weekly reports and conference planners

Related drugs:

H3.3K27M	Glioma	H3.3K27M	Glioma	ONC201 Sensitive: B - Late Trials ONC201 Sensitive : B	ONC201 Sensitive: B - Late Trials ONC201 Sensitive : B
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	KO-947 Sensitive: C2 – Inclusion Criteria KO-947 Sensitive : C2	KO-947 Sensitive: C2 – Inclusion Criteria KO-947 Sensitive : C2
H3.3K27M	Glioma	H3.3K27M	Glioma	bevacizumab + ONC201 Sensitive: C3 – Early Trials bevacizumab + ONC201 Sensitive : C3	bevacizumab + ONC201 Sensitive: C3 – Early Trials bevacizumab + ONC201 Sensitive : C3
BRAF mutation	Thyroid Gland Anaplastic Carcinoma	BRAF mutation	Thyroid Gland Anaplastic Carcinoma	dabrafenib + SCH772984 Sensitive: D – Preclinical dabrafenib + SCH772984 Sensitive : D	dabrafenib + SCH772984 Sensitive: D – Preclinical dabrafenib + SCH772984 Sensitive : D
EGFR overexpression	Glioblastoma	EGFR overexpression	Glioblastoma	ONC201 Resistant: D – Preclinical ONC201 Resistant : D	ONC201 Resistant: D – Preclinical ONC201 Resistant : D
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	darolutamide + ONC201 Resistant: D – Preclinical darolutamide + ONC201 Resistant : D	darolutamide + ONC201 Resistant: D – Preclinical darolutamide + ONC201 Resistant : D
BRAF mutation	Pancreatic Cancer	BRAF mutation	Pancreatic Cancer	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D
KRAS mutation	Melanoma	KRAS mutation	Melanoma	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D
KRAS mutation	Pancreatic Cancer	KRAS mutation	Pancreatic Cancer	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D
BRAF mutation	Melanoma	BRAF mutation	Melanoma	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	DEL-22379 Sensitive: D – Preclinical DEL-22379 Sensitive : D	DEL-22379 Sensitive: D – Preclinical DEL-22379 Sensitive : D
BRAF V600E	Thyroid Gland Carcinoma	BRAF V600E	Thyroid Gland Carcinoma	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D
KRAS G12R	Thyroid Gland Carcinoma	KRAS G12R	Thyroid Gland Carcinoma	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D
HRAS G13R	Thyroid Gland Carcinoma	HRAS G13R	Thyroid Gland Carcinoma	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	KO-947 Sensitive: D – Preclinical KO-947 Sensitive : D	KO-947 Sensitive: D – Preclinical KO-947 Sensitive : D
KRAS mutation	Pancreatic Cancer	KRAS mutation	Pancreatic Cancer	SCH772984 + AZD8186 Sensitive: D – Preclinical SCH772984 + AZD8186 Sensitive : D	SCH772984 + AZD8186 Sensitive: D – Preclinical SCH772984 + AZD8186 Sensitive : D
NRAS mutation	Pancreatic Cancer	NRAS mutation	Pancreatic Cancer	KO-947 Sensitive: D – Preclinical KO-947 Sensitive : D	KO-947 Sensitive: D – Preclinical KO-947 Sensitive : D
NRAS overexpression	Melanoma	NRAS overexpression	Melanoma	DEL-22379 Sensitive: D – Preclinical DEL-22379 Sensitive : D	DEL-22379 Sensitive: D – Preclinical DEL-22379 Sensitive : D
NRAS mutation + BRAF mutation	Melanoma	NRAS mutation + BRAF mutation	Melanoma	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D
GNRHR expression	Triple Negative Breast Cancer	GNRHR expression	Triple Negative Breast Cancer	triptorelin + AEZS 136 + AEZS-134 Sensitive: D – Preclinical triptorelin + AEZS 136 + AEZS-134 Sensitive : D	triptorelin + AEZS 136 + AEZS-134 Sensitive: D – Preclinical triptorelin + AEZS 136 + AEZS-134 Sensitive : D
GNRHR expression	Triple Negative Breast Cancer	GNRHR expression	Triple Negative Breast Cancer	triptorelin + AEZS-129 Sensitive: D – Preclinical triptorelin + AEZS-129 Sensitive : D	triptorelin + AEZS-129 Sensitive: D – Preclinical triptorelin + AEZS-129 Sensitive : D
KRAS G12C	Pancreatic Ductal Adenocarcinoma	KRAS G12C	Pancreatic Ductal Adenocarcinoma	PTPN11 inhibitor + ERK inhibitor Sensitive: D – Preclinical PTPN11 inhibitor + ERK inhibitor Sensitive : D	PTPN11 inhibitor + ERK inhibitor Sensitive: D – Preclinical PTPN11 inhibitor + ERK inhibitor Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	PTPN11 inhibitor + ERK inhibitor Sensitive: D – Preclinical PTPN11 inhibitor + ERK inhibitor Sensitive : D	PTPN11 inhibitor + ERK inhibitor Sensitive: D – Preclinical PTPN11 inhibitor + ERK inhibitor Sensitive : D
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	ONC201 Sensitive: D – Preclinical ONC201 Sensitive : D	ONC201 Sensitive: D – Preclinical ONC201 Sensitive : D

ERK inhibitor

ERK inhibitor

Associations(25)

Associations
(25)